AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$KRMD

KORU Medical Systems Inc (KRMD) Q3 2026 Earnings Call Highlights: Margin Expansion

KORU Medical Systems (KRMD) reported Q3 2026 revenue of $11.6M, up 11% YoY, with gross margin expanding to 65.2%. The company achieved positive net income and adjusted EBITDA, signing new distribution deals in Europe and Africa. However, international sales declined 17% YoY, and pharma services revenue dropped 27%. Management expects Q4 reacceleration and positive cash flow, with Freedom360 regulatory submission on track for late 2026.

Original reporting
finance.yahoo.com
Published Nov 12, 2026, 7:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
KORU Medical Systems Inc (KRMD) Q3 2026 Earnings Call Highlights: Margin Expansion — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$KRMDBullishHigh
01

Why it matters

Earnings beat on margin and raised guidance could attract short‑covering and new buying.

02

Market read

First report of KRMD's Q3 results and FY guidance, providing fresh data for traders.

03

What to watch

International sales decline 17% and pipeline delays could pressure future growth.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

KORU Medical Systems (KRMD) is a micro‑cap biotech focused on self‑administered infusion therapies.

Company-level read

Ticker impact

$KRMDBullishHigh confidence
Context

Q3 earnings released with 11% revenue growth, 500 bps margin expansion and full-year guidance raised to $48‑$48.5M.

Expected impact

likely upward pressure as market prices in higher revenue and margin outlook

Evidence & confidence

The company posted better-than-expected margins and lifted full-year revenue guidance, which typically drives a positive price reaction.

Market effects

Sector

Improves outlook for the specialty pharma and self‑administered infusion market.

Regional

Positive for U.S. specialty pharmacy segment and European distribution partners.

Global

Modest, limited to niche biotech investors.

Counterpoint

What could challenge this read

Margin expansion may be temporary if cost reductions are not sustainable; watch cash burn.

Key entities

  • Executive
    Adam Kalbermatten

    CEO who provided guidance and commentary.

  • Executive
    Tom Adams

    CFO who detailed margin drivers and cash outlook.

Read at source← All news

StoryKORU Medical posts Q3 profit, lifts 2026 revenue and margin outlook

Also covered by

2 outlets

Related articles

$KRMDMed

KORU Medical (KRMD) Q3 2026 Earnings Call Transcript

KORU Medical (KRMD) reported Q3 2026 revenue of $11.6M, up 11% YoY, with margins at 65.2%. The company highlighted growth in domestic and international markets, new distribution partnerships, and progress in its drug pipeline. It achieved positive net income and adjusted EBITDA for the second consecutive quarter, with strategic initiatives aimed at expanding its patient base and market reach.

finance.yahoo.com
$KRMDMed

KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA

KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA MAHWAH, NJ – November 10, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical t

SEC EDGAR 8-K
$KRMDMed

KORU Medical Systems Q2 Earnings Call Highlights

KORU Medical Systems (KRMD) reported Q2 PST revenue of $0.6M, down 35% year over year, citing lower clinical-trial orders and timing. Gross margin rose to 65.1% from 63.5%. The company narrowed full-year revenue guidance to $47.5M-$48.5M, raised gross-margin guidance to 62%-64%, ended with $8.3M cash, and expects positive adjusted EBITDA. It acquired a connected monitoring technology asset and shifted some FDA oncology timing.

yahoo.com
$KRMDMedAI 8/10

KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary

KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.

yahoo.com